CN104478822A - Pharmaceutical composition for treating osteoporosis - Google Patents
Pharmaceutical composition for treating osteoporosis Download PDFInfo
- Publication number
- CN104478822A CN104478822A CN201410696604.4A CN201410696604A CN104478822A CN 104478822 A CN104478822 A CN 104478822A CN 201410696604 A CN201410696604 A CN 201410696604A CN 104478822 A CN104478822 A CN 104478822A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutical composition
- osteoporotic
- cell
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 208000001132 Osteoporosis Diseases 0.000 title abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 230000001009 osteoporotic effect Effects 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- -1 microgranules Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 abstract description 2
- 210000000963 osteoblast Anatomy 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 11
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229940125904 compound 1 Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 229960005309 estradiol Drugs 0.000 description 7
- 229930182833 estradiol Natural products 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010020100 Hip fracture Diseases 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 206010021703 Indifference Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a pharmaceutical composition for treating osteoporosis. The pharmaceutical composition comprises a compound of an effective dose and a pharmaceutically acceptable carrier, wherein the compound has a structure shown in the formula which is shown in the description. The compound provided by the invention shows a certain promoting effect on multiplication and/or differentiation of osteoblast UMR 106 of a rat.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to one and treat osteoporotic pharmaceutical composition.
Background technology
Osteoporosis is worldwide, more and more a to attract people's attention health problem.The current whole world about 200,000,000 people suffers from osteoporosis, its sickness rate leapt to common disease, the 7th of frequently-occurring disease.Estimate that ill total number of persons is more than 200,000,000.Osteoporosis is the modal disease of the elderly.In the U.S. and western countries, more than 55 years old there is the people of half to suffer from the different osteoporosis of degree, and suffer from osteoporosis person up to more than 95% in the elderly of over-65s in postclimacteric women at the age.Along with the progress of the reach of science and the mankind, the average life span constantly extends, and elderly population increase sharply, and osteoporotic sickness rate is also along with appearance increases rapidly.Expectation will be increased to 15.55 hundred million by current 3.23 hundred million to the elderly of the year two thousand fifty whole world over-65s, osteoporosis causes hip fracture generation number to be also increased to 6,260,000 by by current 1,660,000 when the time comes, and wherein the patient of Asia, Latin America, the Middle East and African country will account for more than 70%.According to official statistics, the U.S. reaches 10,000,000,000 dollars for the direct and indirect cost of osteoporosis aspect every year; The fund that the health of Britain and social security institution provide for osteoporosis is every year more than 500,000,000 pounds; France only pays hospitalization cost about 13.5 hundred million French Franc of the patient of 30,000 Hip fracture every year on average.The so huge society that osteoporosis causes and economical load, constitute a serious global problem, caused the very big concern of countries in the world.The arrival of aging society makes osteoporotic incidence increasingly increase, the quality of life of serious threat people.
China is the country that world population is maximum, and wherein elderly population account for 1/2 of Asia elderly population and 1/5 of world population.The osteoporosis epidemiology survey result display in Beijing, Shanghai and Chengdu 3 city, 60-69 year the osteoporotic incidence women of age bracket and the male sex be respectively 60% and about 30%.China's large population base, sufferers of osteoporosis face has reached 6,000 ten thousand ~ 8,000 ten thousand examples, and this brings serious burden to family and society.People according to another statistics national over-65s in 2000 has 1.3 hundred million, accounts for 10.7% of national population, has become typical veteran form country.And the patient suffering from osteoporosis accounts for 90% in these crowds, and the patient of hip fracture will have 12% ~ 40% to die from various complication in 1 year.Also the human action inconvenience of 50% is had in survivor.This not only causes serious body and mind to patient and wrecks, and adds huge manpower and financial resources burden also to family and society simultaneously.Therefore, it is anti-ageing for preventing and treating osteoporosis, prolongs life, ensures the research topic that of quality of life of the people is very urgent.
Summary of the invention
The object of this invention is to provide one and treat osteoporotic pharmaceutical composition.
In order to realize object of the present invention, the invention provides one and treat osteoporotic compound, this compound has having structure:
The present invention also provides one to treat osteoporotic pharmaceutical composition, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
Preferably, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
Preferably, described thinner is lactose.
Preferably, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
The present invention also provides the purposes of compound in the osteoporotic medicine of preparation treatment, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or thinner.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its composition.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, dispersion medium, coating material, tensio-active agent, antioxidant, sanitas (such as antiseptic-germicide, anti-mycotic agent), isotonic agent, absorption delay agent, salt, sanitas, drug stabilizing agent, tackiness agent, vehicle, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceutical Sciences, 18th Ed.Mack PrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of activeconstituents, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention all shows certain promoter action to the propagation of rat kind skeletonization UMR 106 cell and/or differentiation.
Embodiment
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percentage ratio in the present invention is weight percentage.
Experimental example
Material: α-MEM substratum is Gibco Products, and Hepes trypsinase is Sigma Products, UMR106 cell strain, purchased from Peking University's oral surgery laboratory, comes from masschusetts, u.s.a hospital general.Foetal calf serum is purchased from hemopathy institute of the Chinese Academy of Medical Sciences.
Method: with rat human osteosarcoma cell system UMR106 for target cell, adopt the method for controlled observation, take estradiol as positive control, establish Normal group (not dosing simultaneously, only add equal cell suspension and substratum) and blank group (not dosing and cell suspension only add equivalent substratum).Preparation compound is 1 × 10
-8, 1 × 10
-7, 1 × 10
-6mol/L 3 concentration groups, totally 6 groups.Preparation positive control and compound use DMSO.
UMR106 cell cultures and morphological observation: by UMR106 cell cultures in the α-MEM substratum containing 150mL/L foetal calf serum, 25mmol/L Hepes, 100kU/L penicillin, 100mg/L Streptomycin sulphate, put 37 DEG C, cultivate in 50mL/L CO2gas incubator.Get the cell that growth conditions is good, use 2.5g/L tryptic digestion, add α-MEM substratum and make cell suspension, adjustment cell concn is 4 × 10
7l
-1, be inoculated on 4 piece of 12 well culture plate, in culture plate, place 1.5 × 1.5cm slide.Blank group, estradiol positive controls, 1 × 10
-8, 1 × 10
-7, 1 × 10
-6mol/L 3 concentration groups respectively establish 8 multiple holes, and every hole adds cell suspension 2.7mL, corresponding liquid 0.3mL.After 48h, observation of cell metamorphosis under inverted microscope.
The compounds of this invention is on the impact of UMR106 cell proliferation: adjustment cell concn is 2 × 10
7l
-1, be inoculated in 96 well culture plates, every hole adds cell suspension 180 μ L, after 24h, adds the compound of above-mentioned 3 concentration, every hole 20 μ L, separately establishes blank group (do not add compound, only add equal cell suspension).Often group establishes 8 multiple holes, and after continuing to cultivate 48h, adopt tetrazolium salts method to be measure wavelength with 490nm, 655nm is reference wavelength, measures the absorbance A value in each hole.Calculate average proliferation rate.
The compounds of this invention is on the impact of the inside and outside alkaline phosphatase activities of UMR106 cell: adjustment cell concn is 2 × 10
7l
-1, be inoculated on 2 piece of 24 well culture plate, if Normal group, estradiol 1 × 10
-8l
-1positive controls and compound 1 × 10
-8, 1 × 10
-7, 1 × 10
-63 concentration groups of mol/L, totally 5 groups, often group establishes 8 multiple holes, according to the method for Joha AP, after dosing 72h, adopts p-nitrophenyl matter KINETIC METHOD to measure in cell and the alkaline phosphatase activities of substratum.
MAIN OUTCOME MEASURES: the compounds of this invention 1 × 10
-8, 1 × 10
-7, 1 × 10
-63 concentration groups of mol/L are on the impact of UMR106 cell proliferation and inside and outside alkaline phosphatase activities.
Statistical analysis: completed by SPSS statistical software.Data are used
represent, t inspection between organizing, namely P<0.05 thinks to have significant difference.
Result
The impact that the compound of different concns changes UMR106 cellular form
After adding compound cultivation 48h in substratum, cell quantity showed increased compared with control group, karyokinetic phase, is common.Normal group is after cultivation 48h, and control group UMR106 cell proliferation is slow, has no matrix and piles up.Add compound 1 × 10
-8after mol/L cultivates 48h, obviously, cell count increases UMR106 propagation, and a small amount of matrix is piled up.Add compound 1 × 10
-7after mol/L cultivates 48h, cell count obviously increases, and overlapping growth, matrix is piled up obviously.Add compound 1 × 10
-6after mol/L cultivates 48h, cell is bred in a large number, connects in flakes, matrix bulk deposition, overlapping growth.
The proliferation of the compounds of this invention to UMR106 cell sees the following form
Cell is after compound treatment 48h, and detect through tetrazolium salts method, relative to control group, 3 administration groups all have significant difference compared with control group.
Compound is on the impact of alkaline phosphatase activities in UMR106 cell
Cell is after compound treatment when 24h, 48h, and detect through p-nitrophenyl matter KINETIC METHOD, in cellular control unit, alkaline phosphatase activities is respectively 713.12 ± 12.15,2281.32 ± 7.62 μ kat/g, compound 1 × 10
-6in mol/L group cell, alkaline phosphatase activities is respectively 823.12 ± 12.31,2415.41 ± 15.86 μ kat/g, and difference has significant compared with control group.Estradiol 1 × 10
-8mol/L group 24h, 48h after treatment, in cell, alkaline phosphatase activities is respectively 275.19 ± 18.63,2355.48 ± 15.62 μ kat/g, and difference has significant compared with control group.72h after process, each concentration group of compound and estradiol 1 × 10
-8mol/L group group is compared with control group, and in cell, alkaline phosphatase activities has the trend of enhancing, but no difference of science of statistics.
Compound is on the impact of UMR106 extracellular alkaline phosphatase activities
After 24h, control group substratum activity change of Alkaline phosphatase is 652.83 ± 11.31 μ kat/g, compound 1 × 10
-6mol/L group is 781.62 ± 11.58 μ kat/g, has significant difference compared with control group.Estradiol 1 × 10
-8mol/L group and compound 1 × 10
-7mol/L group is respectively 728.85 ± 9.87 μ kat/g and 733.18 ± 15.32 μ kat/g, has significant difference compared with control group.Compound 1 × 10
-8mol/L group is 671.32 ± 14.27 μ kat/g, with control group indifference.48h and 72h after treatment, each concentration group of compound and estradiol 1 × 10
-8mol/L group is compared with control group, and extracellular alkaline phosphatase activities has the trend of enhancing, but no difference of science of statistics.
Claims (7)
1. treat an osteoporotic compound, it is characterized in that, this compound has having structure:
2. treat an osteoporotic pharmaceutical composition, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the osteoporotic pharmaceutical composition for the treatment of according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
4. the osteoporotic pharmaceutical composition for the treatment of according to claim 3, is characterized in that, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
5. the osteoporotic pharmaceutical composition for the treatment of according to claim 4, is characterized in that, described thinner is lactose.
6. the osteoporotic pharmaceutical composition for the treatment of according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
7. the purposes of compound in the osteoporotic medicine of preparation treatment, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410696604.4A CN104478822B (en) | 2014-11-26 | 2014-11-26 | One is treated osteoporotic pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410696604.4A CN104478822B (en) | 2014-11-26 | 2014-11-26 | One is treated osteoporotic pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104478822A true CN104478822A (en) | 2015-04-01 |
| CN104478822B CN104478822B (en) | 2016-05-11 |
Family
ID=52753452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410696604.4A Expired - Fee Related CN104478822B (en) | 2014-11-26 | 2014-11-26 | One is treated osteoporotic pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104478822B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105218465A (en) * | 2015-11-14 | 2016-01-06 | 刘杰 | A kind of pharmaceutical composition for the treatment of mammary cancer |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011020849A1 (en) * | 2009-08-18 | 2011-02-24 | Rheinische Friedrich-Wilhelms Universität | Cytohesin inhibitors |
| DE102010013716A1 (en) * | 2010-03-31 | 2011-10-06 | Rheinische Friedrich-Wilhelms-Universität Bonn Körperschaft des öffentlichen Rechts | Use of amide compounds in combination with epidermal growth factor receptor inhibitor comprising gefitinib and/or erlotinib for the treatment of cancer e.g. lung cancer, colon cancer, bladder cancer, breast cancer and/or ovarian cancer |
| CN102976973A (en) * | 2004-06-07 | 2013-03-20 | 田纳西大学研究基金会 | Selective androgen receptor modulator and method for using thereof |
| CN103338765A (en) * | 2010-12-03 | 2013-10-02 | 阿勒根公司 | Novel phenyl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
-
2014
- 2014-11-26 CN CN201410696604.4A patent/CN104478822B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102976973A (en) * | 2004-06-07 | 2013-03-20 | 田纳西大学研究基金会 | Selective androgen receptor modulator and method for using thereof |
| WO2011020849A1 (en) * | 2009-08-18 | 2011-02-24 | Rheinische Friedrich-Wilhelms Universität | Cytohesin inhibitors |
| DE102010013716A1 (en) * | 2010-03-31 | 2011-10-06 | Rheinische Friedrich-Wilhelms-Universität Bonn Körperschaft des öffentlichen Rechts | Use of amide compounds in combination with epidermal growth factor receptor inhibitor comprising gefitinib and/or erlotinib for the treatment of cancer e.g. lung cancer, colon cancer, bladder cancer, breast cancer and/or ovarian cancer |
| CN103338765A (en) * | 2010-12-03 | 2013-10-02 | 阿勒根公司 | Novel phenyl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
Non-Patent Citations (2)
| Title |
|---|
| BEN-REN LIAO ET AL.: "Synthesis and structureeactivity relationship of non-phosphorus-based fructose-1,6-bisphosphatase inhibitors: 2,5-Diphenyl-1,3,4-oxadiazoles", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
| PAN, JIAXING ET AL.: "Research on 2,5-Disubstituted oxadiazoles", 《CHEM. J. CHINESE UNIV.》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105218465A (en) * | 2015-11-14 | 2016-01-06 | 刘杰 | A kind of pharmaceutical composition for the treatment of mammary cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104478822B (en) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101116503A (en) | Health products for reducing blood sugar and method for preparing the same | |
| Ma et al. | Topical application of temperature-sensitive caerin 1.1 and 1.9 gel inhibits TC-1 tumor growth in mice | |
| Choda | Medicinal value of Cordyceps sinensis | |
| TW200936152A (en) | Plant derived compounds containing the same for the treatment of cervical cancer | |
| CN105769833B (en) | Application of the syringaldehyde in preparing ionising radiation and causing intestinal tract injury protection medicine | |
| CN104478822A (en) | Pharmaceutical composition for treating osteoporosis | |
| CN102198195A (en) | Antioxidative medicinal composition | |
| Tao et al. | Niacin treatment prevents bone loss in iron overload osteoporotic rats via activation of SIRT1 signaling pathway | |
| CN108969515A (en) | HIF-2 alpha inhibitor is used to prepare the purposes of prevention and treatment acute high altitude reaction drug | |
| CN102058854B (en) | Chinese medicine for treating malignant lymphoma | |
| CN102166353B (en) | A spray for treating diseases caused by human papilloma viruses and a preparation method | |
| CN105136781B (en) | Application of fat factor GREM2 as drug target in drugs for treating obesity | |
| CN101485784B (en) | Chinese medicament preparation for treating male infertility, aspermia and asthenospermia | |
| CN111870689A (en) | Application of nattokinase in medicine for treating osteoporosis | |
| CN106491589A (en) | Applications of the Linderolide H in treatment acute gout medicine is prepared | |
| CN102772398A (en) | Application of dihydromyricetin in preparation of drug preventing and treating influenza | |
| CN103251636A (en) | Medicament for treating Candida infections and diseases caused by Candida, and preparation method thereof | |
| CN105111150A (en) | Medicine composition for treating osteoporosis | |
| CN109602775B (en) | Application of chicory alcohol extract in preparation of anti-breast cancer drugs | |
| CN102512359B (en) | Mangiferin cream with anti-herpes virus effect | |
| CN104059130B (en) | about ST2 protein inhibitor polypeptide and application thereof | |
| CN103877126B (en) | Knurl lid intends the pharmaceutical usage of shelf fungus and the pharmaceutical composition for the treatment of tumour | |
| CN104017055B (en) | A kind of about ST2 protein inhibitor polypeptide and application thereof | |
| CN109908155A (en) | The medicinal usage of tanshinone IIA | |
| CN103892956B (en) | A kind of sheath with antivirus action |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Tao Inventor before: Zhang Huan |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160224 Address after: 273200 Surabaya County Chinese medicine hospital, 092 Si Si Road, Si county, Jining, Shandong, Surabaya Applicant after: Wang Tao Address before: 200062 East China Normal University, Putuo District, Zhongshan North Road, 3663, Shanghai Applicant before: Zhang Huan |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160511 Termination date: 20161126 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |